Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Arjo, Audiocast, Q3'25

By Inderes10/22/2025, 6:00 AM
Arjo

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Niclas Sjöswärd
00:00 - 09:36

Hello and good morning to everyone, and welcome to Arjo's Q3 2025 Earnings Call. With me here today, I have Christofer Carlsson, our CFO. We will provide some details on the quarter three report that we released an hour ago. The agenda looks as usual and includes a summary of activities and results from quarter three, the balance sheet items, and the outlook for 2025. Before we open up for questions, we intend to keep this call to an hour and finish no later than 9:00. Next slide please. We closed the third quarter in a solid manner and observed continued demand, with organic net sales growth aligning well with our targeted range. And as expected, it is sequentially higher than the first half of the year. We had continued strong momentum for our service business, now also supported by stronger growth in our capital sales, while our rental business was slower this quarter. Our North America business is showing stable growth this quarter, while global sales are now delivering from a strong order book and healthy customer demand, demonstrating the strongest growth quarter in several years. This altogether makes us close the quarter with a +3.8% organic net sales growth for the group. We continue to have a materially higher order book than the same period last year, and we are looking forward to a strong finish of the year in quarter four. Our gross margin came in at 41.1% compared to last year's 42.0%. We continue to receive support from lower material costs and price adjustments. While these improvements are offset by currency and US tariff headwinds in quarter three. We also had an unfavorable geographic mix impact due to the relatively higher sales volume in global sales and the rest of the world markets, as well as higher medical bed sales, which also impact the gross margin. Excluding currency and US tariffs. The gross margin would have been on par with last year, despite the product mix effects. For the rest of 2025, we will continue to drive efficiency focus throughout the value chain based on the plans that we have put in place. For example, within the supply chain, our focus on price adjustments will obviously also remain to secure compensation for salary inflation and the US tariffs. The organization is doing a good job on the OpEx side, and we have been able to slow down the cost increase compared to quarter two. Our efforts to increase cost efficiency are showing effects, bringing down the organic OpEx growth compared to last year, to almost flat. Adjusted EBITDA for the quarter increased to 436 million, compared to 434 million in quarter three last year, a result stemming from higher sales and an improved Opex to sales ratio. The adjusted EBITDA margin improved by 0.6 percentage points versus last year. Overall, our underlying profitability continues to improve, and excluding the effects of currencies and tariffs, the adjusted operating profit increased by over 20%. Our operational cash flow came in at 446 million, leading to a cash conversion of 105% for the quarter. Both cash flow and cash conversion improved compared to the same period last year. So in summary, we are delivering a stable third quarter of 2025. Our underlying business is developing in a solid way, and we can see how our business model with capital, rental, and service is helping us deliver stability, growth, and an underlying earnings trend. In addition to this, we see several important markets showing good signs of increased activity levels and healthy demand for our products and solutions. We see increased sales growth and an overall positive momentum in the business, which makes me believe in a strong finish to 2025 in quarter four. Next slide please. Our North America business continues to show stable growth this quarter in our largest market, the US. This quarter, we have stable growth, but it is more modest sequentially compared to the last quarter due to the timing of customer deliveries following a very strong previous quarter. We have positive momentum in the US business and an overall high customer activity level, and we expect a stronger quarter. And we also expect sales growth to increase again in quarter four. Then moving over to Western Europe and the rest of the world that make up the global sales region. In quarter three, this region grew net sales organically by 5.7%, driven by a strong order book and high customer activity levels. In Western Europe, the organic net sales growth was 2.1% despite the continued weak market development in the United Kingdom. Several other European countries saw good demand and strong organic net sales growth in the quarter, such as France, Germany, Italy, and Spain. Our service business in Western Europe continued to develop well in the quarter as well. Our business in the rest of the world markets had an organic net sales growth of 15.9% in the quarter, with most markets performing well. Many important markets grew double digits in the quarter, with India standing out with an impressive 40% growth for the second sequential quarter, which now makes India one of the top ten markets for Arjo. In addition, Australia, Africa, and Singapore all performed well, and we entered into the last quarter of the year with overall good momentum in the rest of the world markets. Next slide please. Our gross margin came in at 41.1% compared to last year's 42.0%. We continue to receive support from lower material costs and price adjustments. These improvements are offset by currency and US tariff headwinds in quarter three. We also had a negative impact from geographic and product mix due to relatively higher sales volumes in global sales. The rest of the world region experienced a high volume of medical beds sales, excluding currency and tariffs. The gross margin would have been on par with last year despite the geo and product mix headwinds. We are, as before, working hard to mitigate the headwinds with continued long-term efficiency gains throughout the value chain, including a solid focus on continuous supply chain efficiencies. We will also continue to work on price adjustments as one part of the puzzle to mitigate the US tariffs and other external cost increases. Next slide, please. Adjusted EBIT in quarter three was in line with last year, despite headwinds in gross profit, due to increased sales and an improved OpEx to sales ratio. The Ebit margin improved slightly. Excluding the effects of currencies and tariffs, the adjusted Ebit increased over 20%. On the OpEx side, we have been able to slow down the cost increase compared to quarter two, and our actions to mitigate cost increases are showing effect, which makes organic OpEx development now almost flat compared to last year and gives us an improved OpEx to sales ratio. I'm happy to see the response from the organization with a much sharper focus on cost improvements over the last quarters, and we have now set the tone going forward to manage OpEx in a good way. We had a negative impact from the revaluation of AP and AR amounting to -4 million SEK in the quarter, which was recorded under other expenses. This was -13 million SEK in the same quarter last year. Adjusted EBITDA for the quarter was 436 million SEK, versus 434 million SEK in quarter three last year, a result coming from higher sales and improved CapEx to sales ratio. The adjusted EBITDA margin improved by 0.6 percentage points versus last year. Restructuring costs came in at -13 million SEK in the quarter, related to ongoing improvements in the global sales structure to enhance the cost situation for the future. Next slide please. And here I hand over to our CFO Christofer Carlsson.

Christofer Carlsson
09:36 - 12:00

Thank you Niclas. Operating cash flow improved significantly by 241 million SEK compared to the second quarter of 2025, and was 9 million SEK higher year over year, primarily due to good receivable collection, which includes the vast majority of the temporary VAT receivable from Q2. The increase in inventory is modest and in line with last year. Our supply chain inventory is declining and instead the goods are now residing in sales units for deliveries in Q4. As a result of the decline in working capital, working capital days decreased to 82, down from 83 in the second quarter of 2025, combined with lower interest costs. This led to an operating cash flow of 446 million SEK, versus 437 million in Q3 2024. Consequently, cash conversion was 105% compared to 102% last year. The last quarter is typically our strongest cash flow quarter for the full year. We expect to be in line with last year, just below our full-year target of 80% for the cash conversion. For reference, cash flow from investing activities was 148 million SEK, compared to 190 million SEK last year. The decrease is mainly due to a 38 million SEK reduction in business acquisitions. This year, we made a small 5 million SEK acquisition in Australia of the Arden service business, while last year, we acquired Aeromed in Germany. Next slide please. The decrease in net debt this quarter is mainly due to improved operating cash flow. Our financial net improved by 41 million SEK from Q3 2024, driven by lower interest rates. Our cash position remains strong. Net debt to adjusted EBITDA improved versus Q2 of this year and came in at 2.2, which is on par with Q3 24. Our equity ratio stood at 49.5%, up from 48.7% in Q2 25, mainly due to the profit made in the quarter. With that, I hand it back to Niclas Sjöswärd.

Niclas Sjöswärd
12:01 - 14:23

Thank you Christofer. Let's also update you on some other business highlights. During the quarter, we received US FDA approval for our fetal monitors in our diagnostics business. Furthermore, we completed two small supplementary acquisitions that will strengthen our local businesses in the Netherlands and Australia, both of which are expected to start contributing positively during the fourth quarter of this year. During the quarter, we also received the latest ESG rating from MSCI, and Arjo was upgraded to the highest possible scoring, triple A. And finally, during the quarter, it was announced that Andréas Elgaard has been appointed as president and CEO starting in January. Next slide please. Our outlook for 2025 is that the organic net sales growth will be well within the group's target interval of 3 to 5%. With that, I would like to summarize today's telecom conference. We have continued healthy demand for our products and solutions, with net sales growth comfortably in line with our target and sequentially higher growth than the first half of the year. As expected, global sales are the growth engine for the quarter and are showing the highest sales growth in several years. Several markets are standing out positively, and we see good opportunities to continue to build on this momentum moving forward. We see clearly that our cost efficiency measures are paying off, and our focus in this area will continue moving forward. The underlying profitability continues to improve as seen in this quarter, with adjusted EBIT, excluding the effects of currency and tariffs, increasing over 20%. Our cash flow and cash conversion improved in the quarter, and our work to improve working capital is paying off. Overall, it has been a positive quarter for us, despite the challenging macro environment and related uncertainties, and we remain confident in our ability to deliver a strong finish to the year in the fourth quarter. So with that, we can open up for questions. Moderator, please go ahead.

Operator
14:26 - 14:46

If you wish to ask a question, please dial the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key on your telephone keypad. The next question comes from Ludwig Gemunder from Handelsbanken. Please go ahead.

Ludwig Gemunder
14:49 - 15:21

Good morning and thank you for taking my questions. My first question would be on the tariff impact for the quarter. Is it possible for you to quantify the general impact that you saw from tariffs over the quarter? Is it close to the 15% rate or is it still at the lower end of the 15% rate? And then my second question is around the development in the UK, which we know is a weak market for you right now. Do you see any changes in the development there? Any comment would be helpful. Next slide please.

Niclas Sjöswärd
15:23 - 16:12

Yeah. Thank you, Ludwig. Regarding the tariffs, the way we explain the impact is in million SEK, as we did last quarter. So we are slightly above 10 million SEK, experiencing a negative impact in the quarter, in quarter three. So it's a similar impact as last quarter. On the UK market, we are working very hard to find a way forward in the difficult market situation. Of course, we have plans in place. With the uncertainties surrounding NHS restructuring in the market, we think that we can improve from where we are, but it will continue to be a difficult market for the rest of the year. I think we need to see it like that.

Ludwig Gemunder
16:15 - 16:33

Okay. Thank you. And, Daniel, one more, if I may. You have had a positive development in your net debt to EBITDA. Do you have any plans, or could we expect any significant mergers and acquisitions going forward? Do you expect any changes or differences?

Niclas Sjöswärd
16:34 - 16:51

Yeah, we have a good development there. But, of course, if there are any M&A opportunities that we see as beneficial for our business moving forward, we are open to them. But short term, nothing in the pipeline that we can talk about.

Ludwig Gemunder
16:53 - 16:55

Okay. Thank you.

Operator
17:01 - 17:06

The next question comes from Sten Gustafson from ABG Sundal Collier. Please go ahead.

Sten Gustafson
17:08 - 17:48

Of course, we have plans in place. Good morning. A question about the US market. It sounds like you're quite upbeat there. I think you mentioned that you have a strong order intake and expect strong deliveries in Q4. I assume you don't want to comment on the sort of growth rate in orders you have received there, but that could be the first one. But maybe you can comment on what type of products you see growth for in Q4 in the US, please.

Niclas Sjöswärd
17:49 - 18:20

Yes. What I can say is that we have a strong order book in the US. Material is stronger than the same period last year. That's why we are optimistic. We had some timing issues in quarter three. We grew very, very strongly in quarter two. More modest in quarter three. But the order book is still there and should be delivered. And the piece of the order book that has been growing quickest is the patient handling part in the US.

Sten Gustafson
18:24 - 18:28

Excellent. Thank you. And Randall, how is the situation in the US?

Niclas Sjöswärd
18:30 - 18:45

It's comparable to last year. So there's no significant growth in quarter three. We are a little bit waiting and anticipating the flu season, which has not kicked in yet. It will depend on the magnitude of the flu season, how quarter four plays out, I can say.

Sten Gustafson
18:46 - 18:57

Okay, thank you. My second question would be on India, if you could comment on how much lower profitability you have there generally compared to the group average.

Niclas Sjöswärd
18:59 - 18:59

Yeah.

Sten Gustafson
19:00 - 19:00

Gross margin.

Niclas Sjöswärd
19:00 - 19:34

Yes, exactly. So, I think generally speaking, it's not so bad in India if you put it that way. But Medical Beds was one of the drivers of the sales in India this quarter. You get a combination of market and product mix in quarter three. You could say. So that's what we're trying to convey there. Otherwise, generally we are selling our products as premium products in India. And with that comes lower profitability than in Western Europe and North America obviously. But for being an emerging market, not bad at all.

Sten Gustafson
19:36 - 19:37

But the order book is still there and should be delivered. Excellent. Thank you very much.

Operator
19:43 - 20:03

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Niclas Sjöswärd
20:05 - 20:12

But the order book is still there and should be delivered. Thank you very much for joining and listening to our Q3 update. And we close the meeting with that.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…